| Literature DB >> 31494598 |
Nóra Kovács1, Orsolya Varga2, Attila Nagy1, Anita Pálinkás1, Valéria Sipos1, László Kőrösi3, Róza Ádány1,4,5, János Sándor1.
Abstract
OBJECTIVES: The objectives of our study were (1) to investigate the association between gender of the general practitioner (GP) and the quality of primary care in Hungary with respect to process indicators for GP performance and (2) to assess the size of the gender impact. STUDYEntities:
Keywords: Gender; General practitioner; PRIMARY CARE; Process indicators; Quality of care
Mesh:
Year: 2019 PMID: 31494598 PMCID: PMC6731795 DOI: 10.1136/bmjopen-2018-027296
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Definition and the target group of the studied PHC indicators
| Indicator | Target group | Definition |
| Influenza immunisation | Patients over 65 years | Proportion of PHC patients, age 65 years and older, who received an influenza immunisation in the previous 12 months |
| Mammography screening | 45–65 years-old female PHC patients | Proportion of female PHC patients, age 45–65 years, who received mammography in the previous 24 months |
| Serum creatinine measurement | Patients who redeemed antihypertensive drug at least four times in the previous 12 months (considered as patients with hypertension) | Proportion of PHC patients with hypertension screened for serum creatinine in the previous 12 months |
| Lipid measurement | Patients who redeemed antihypertensive drug at least four times in the previous 12 months (considered as patients with hypertension) | Proportion of PHC patients with hypertension and/or diabetes screened for lipid abnormalities in the previous 12 months |
| Beta-blocker application | Patients with AMI or CABG or PTCA | Proportion of patients with AMI, CABG or PTCA who used beta-blockers in the previous 12 months |
| HbA1c measurement | ATC A10 drug users | Proportion of PHC patients with diabetes mellitus screened for HbA1c in the previous 12 months |
| Eye examination | ATC A10 drug users | Proportion of PHC patients with diabetes mellitus who attended eye examination in the previous 12 months |
| Management of COPD | ATC R03 drug users and patients with COPD | Proportion of PHC patients with COPD who attended pulmonary function testing in the previous 12 months |
| Composite indicator | Total number of patients of each studied indicator | Proportion of PHC patients provided with recommended care; a general indicator of performance of GMP by summarising the number of care events and size of target populations of each studied indicator |
AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; GMP, general medical practice; HbA1c, haemoglobin A1c; PHC, primary healthcare; PTCA, percutaneous transluminal coronary angioplasty.
Patient-level, physician-level and organisational characteristics of GMPs
| All GMPs | GMPs with male GPs | GMPs with female GPs | P value | |
| Number of GMPs | n=4575 | n=2362 (51.6%) | n=2213 (48.4%) | |
| Age of GP, mean (SD) | 56.6 (11.2) | 57.8 (11.3) | 55.3 (10.9) | <0.001 |
| Number GMPs’ patients | ||||
| Male | 3 360 154 (46.6%) | 1 794 560 (47.7%) | 1 565 594 (45.5%) | <0.001 |
| Female | 3 847 032 (53.4%) | 1 968 309 (52.3%) | 1 878 723 (54.6%) | |
| Total | 7 207 186 | 3 762 869 | 3 444 317 | |
| Age (years) groups of patients | ||||
| 18–19 | 121 802 (1.69%) | 67 609 (1.8%) | 54 193 (1.57%) | <0.001 |
| 20–24 | 483 058 (6.7%) | 256 773 (6.82%) | 226 285 (6.57%) | |
| 25–29 | 539 957 (7.49%) | 280 817 (7.46%) | 259 140 (7.52%) | |
| 30–34 | 553 972 (7.69%) | 283 279 (7.53%) | 270 693 (7.86%) | |
| 35–39 | 690 907 (9.59%) | 352 765 (9.37%) | 338 142 (9.82%) | |
| 40–44 | 752 110 (10.44%) | 389 203 (10.34%) | 362 907 (10.54%) | |
| 45–49 | 647 431 (8.98%) | 339 710 (9.03%) | 307 721 (8.93%) | |
| 50–54 | 534 270 (7.41%) | 284 021 (7.55%) | 250 249 (7.27%) | |
| 55–59 | 561 965 (7.8%) | 298 506 (7.93%) | 263 459 (7.65%) | |
| 60–64 | 665 236 (9.23%) | 347 758 (9.24%) | 317 478 (9.22%) | |
| 65–69 | 542 777 (7.53%) | 283 530 (7.53%) | 259 247 (7.53%) | |
| 70–74 | 416 851 (5.78%) | 215 507 (5.73%) | 201 344 (5.85%) | |
| 75–79 | 316 345 (4.39%) | 165 255 (4.39%) | 151 090 (4.39%) | |
| 80–84 | 213 912 (2.97%) | 111 762 (2.97%) | 102 150 (2.97%) | |
| 85–89 | 117 420 (1.63%) | 61 119 (1.62%) | 56 301 (1.63%) | |
| >90 | 49 322 (0.68%) | 25 378 (0.67%) | 23 944 (0.7%) | |
| Relative education, mean (SD) | 1.000 (0.1) | 0.989 (0.2) | 1.026 (0.1) | <0.001 |
| Types of settlement | ||||
| Urban | 3143 (68.7%) | 1465 (62.0%) | 1678 (75.8%) | <0.001 |
| Rural | 1432 (31.3%) | 897 (37.9%) | 535 (24.2%) | |
| GMP size (number of patients) | ||||
| <800 | 126 (2.8%) | 66 (2.9%) | 60 (2.7%) | <0.001 |
| 801–1200 | 646 (14.1%) | 322 (13.6%) | 324 (14.6%) | |
| 1201–1600 | 1464 (32.0%) | 690 (29.2%) | 774 (34.9%) | |
| 1601–2000 | 1415 (30.9%) | 742 (31.4%) | 673 (30.4%) | |
| >2000 | 924 (20.2%) | 542 (22.9%) | 382 (17.3%) | |
GMP, general medical practice; GP, general practitioner.
The number of patients received the care, the number of people in the target groups and the proportion of patients received the care in 2016 for the whole country by gender of GPs with 95% CIs
| Number of patients received the care | Number of people in target group | Proportion of patients received the care | |||||
| Male GPs | Female GPs | Male GPs | Female GPs | Male GPs | Female GPs | P value | |
| Influenza immunisation | 172 150 | 159 893 | 865 187 | 796 380 | 19.9%(19.8–19.9) | 20.1%(19.9–20.2) | 0.004 |
| Mammography screening | 304 907 | 299 137 | 681 141 | 640 293 | 44.7%(44.6–44.9) | 46.7%(46.5–46.9) | <0.001 |
| Serum creatinine measurement | 814 819 | 785 950 | 1 225 158 | 1 108 168 | 66.5%(66.4–66.6) | 70.9%(70.8–71.0) | <0.001 |
| Lipid measurement | 752 737 | 735 502 | 1 261 490 | 1 139 843 | 59.7%(59.6–59.8) | 64.5%(64.4–64.6) | <0.001 |
| Beta-blocker application | 48 202 | 42 184 | 90 112 | 80 723 | 53.5%(53.2–53.8) | 52.3%(51.9–52.6) | <0.001 |
| HbA1c measurement | 192 370 | 179 474 | 250 575 | 222 690 | 76.8%(76.6–76.9) | 80.6%(80.4–80.8) | <0.001 |
| Eye examination | 95 617 | 91 995 | 250 575 | 222 690 | 38.2%(37.9–38.4) | 41.3%(41.1–41.5) | <0.001 |
| Management of COPD | 75 154 | 69 835 | 97 213 | 88 345 | 77.3%(77.1–77.6) | 79.1%(78.8–79.3) | <0.001 |
| Composite indicator | 2 455 956 | 2 363 970 | 4 721 451 | 4 299 132 | 52.0%(51.9–52.1) | 54.9%(54.9–55.0) | <0.001 |
COPD, chronic obstructive pulmonary disease; GPs, general practitioners; HbA1c, haemoglobin A1c.
Influence of female gender of GPs (OR, 95% CIs, robust standard errors) on the primary healthcare indicators according to multilevel logistic regression analysis controlled for age of GP, age and gender of the patients, relative education of patients, practice size, types of settlement and regional location of GMP in 2016 and the ICC of tested models
| Indicators | OR | 95% CI | Robust SE | ICC (%) |
| Influenza immunisation (over 65 years) | 1.03 | 0.98 to 1.09 | 0.028 | 17.9 |
| Mammography screening (age 45–65 years) | 1.05 | 1.03 to 1.08 | 0.014 | 4.8 |
| Serum creatinine measurement | 1.14 | 1.12 to 1.17 | 0.014 | 4.1 |
| Lipid measurement | 1.14 | 1.11 to 1.16 | 0.014 | 4.6 |
| Beta-blocker application | 0.98 | 0.96 to 1.01 | 0.013 | 2.4 |
| HbA1c measurement | 1.18 | 1.14 to 1.23 | 0.022 | 8.4 |
| Eye examination | 1.06 | 1.03 to 1.08 | 0.013 | 3.3 |
| Management of COPD | 1.05 | 1.01 to 1.09 | 0.019 | 4.9 |
| Composite indicator | 1.08 | 1.07 to 1.10 | 0.008 | 1.8 |
Reference group is male GPs.
COPD, chronic obstructive pulmonary disease; GMP, general medical practice; GPs, general practitioners; HbA1c, haemoglobin A1c; ICC, intraclass correlation coefficient.
Number of observed and expected care events in 2016, with absolute differences and attributable proportion estimations (with 95% CI) in Hungary among 3 762 869 patients provided by male GPs
| Indicators | Number of observed cases | Number of expected cases | Absolute difference | Attributable proportion |
| Influenza immunisation | 172 150 | 173 813 | −1 663 | 0.97% (0.49%–1.44%) |
| Screening mammography | 304 907 | 318 192 | −13 285 | 4.36% (4%–4.71%) |
| Serum creatinine measurement | 814 819 | 866 949 | −52 130 | 6.4% (6.18%–6.61%) |
| Lipid measurement | 752 737 | 812 459 | −59 723 | 7.93% (7.71%–8.16%) |
| Beta-blocker application | 48 202 | 47 037 | 1 165 | 2.42% (1.53%–3.31%) |
| HbA1c measurement | 192 370 | 202 170 | −9 801 | 5.09% (4.65%–5.54%) |
| Eye examination | 95 617 | 103 302 | −7 686 | 8.04% (7.4%–8.67%) |
| Management of COPD | 75 154 | 76 901 | −1 748 | 2.33% (1.61%–3.04%) |
| Total (composite indicator) | 2 455 956 | 2 600 827 | −144 871 | 5.9% (5.77%–6.02%) |
COPD, chronic obstructive pulmonary disease; GPs, general practitioners; HbA1c, haemoglobin A1c.